Aritinercept
Autoimmune Diseases
Discovery/PreclinicalActive Development
Key Facts
Indication
Autoimmune Diseases
Phase
Discovery/Preclinical
Status
Active Development
Company
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a Canadian biotech company with a mission to deliver transformative therapies for autoimmune diseases. Its core achievement is the successful FDA approval and commercialization of LUPKYNIS, a first-in-class oral treatment for lupus nephritis. The company's strategy is to maximize the global potential of LUPKYNIS while leveraging its expertise to develop a pipeline of novel candidates, including a dual BAFF/APRIL inhibitor, to build a sustainable, multi-product autoimmune franchise.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Gavocabtagene autoleucel | Astellas | Phase 1/2 |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |
| I&I Portfolio | Third Arc Bio | Pre-clinical |
| Undisclosed Platform Programs | Zag Bio | Preclinical |
| E-602 | Palleon Pharmaceuticals | IND-Enabling |
| DIASPOT Platform Expansion | DIAsource ImmunoAssays | Commercial & Development |